These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18444920)

  • 1. Islet transplantation for brittle type 1 diabetes: the UIC protocol.
    Gangemi A; Salehi P; Hatipoglu B; Martellotto J; Barbaro B; Kuechle JB; Qi M; Wang Y; Pallan P; Owens C; Bui J; West D; Kaplan B; Benedetti E; Oberholzer J
    Am J Transplant; 2008 Jun; 8(6):1250-61. PubMed ID: 18444920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.
    Faradji RN; Tharavanij T; Messinger S; Froud T; Pileggi A; Monroy K; Mineo D; Baidal DA; Cure P; Ponte G; Mendez AJ; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Dec; 86(12):1658-65. PubMed ID: 19104401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients.
    Koh A; Imes S; Kin T; Dinyari P; Malcolm A; Toso C; Shapiro AM; Senior P
    Transplantation; 2010 Feb; 89(3):361-5. PubMed ID: 20145529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.
    Froud T; Ricordi C; Baidal DA; Hafiz MM; Ponte G; Cure P; Pileggi A; Poggioli R; Ichii H; Khan A; Ferreira JV; Pugliese A; Esquenazi VV; Kenyon NS; Alejandro R
    Am J Transplant; 2005 Aug; 5(8):2037-46. PubMed ID: 15996257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.
    Zoso A; Serafini P; Lanzoni G; Peixoto E; Messinger S; Mantero A; Padilla-Téllez ND; Baidal DA; Alejandro R; Ricordi C; Inverardi L
    PLoS One; 2016; 11(6):e0157245. PubMed ID: 27285580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes.
    Bellin MD; Kandaswamy R; Parkey J; Zhang HJ; Liu B; Ihm SH; Ansite JD; Witson J; Bansal-Pakala P; Balamurugan AN; Papas KK; Sutherland DE; Moran A; Hering BJ
    Am J Transplant; 2008 Nov; 8(11):2463-70. PubMed ID: 18808408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience.
    Qi M; Kinzer K; Danielson KK; Martellotto J; Barbaro B; Wang Y; Bui JT; Gaba RC; Knuttinen G; Garcia-Roca R; Tzvetanov I; Heitman A; Davis M; McGarrigle JJ; Benedetti E; Oberholzer J
    Acta Diabetol; 2014 Oct; 51(5):833-43. PubMed ID: 25034311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
    Shapiro AM; Lakey JR; Ryan EA; Korbutt GS; Toth E; Warnock GL; Kneteman NM; Rajotte RV
    N Engl J Med; 2000 Jul; 343(4):230-8. PubMed ID: 10911004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.
    Turgeon NA; Avila JG; Cano JA; Hutchinson JJ; Badell IR; Page AJ; Adams AB; Sears MH; Bowen PH; Kirk AD; Pearson TC; Larsen CP
    Am J Transplant; 2010 Sep; 10(9):2082-91. PubMed ID: 20883542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol.
    Rickels MR; Liu C; Shlansky-Goldberg RD; Soleimanpour SA; Vivek K; Kamoun M; Min Z; Markmann E; Palangian M; Dalton-Bakes C; Fuller C; Chiou AJ; Barker CF; Luning Prak ET; Naji A
    Diabetes; 2013 Aug; 62(8):2890-7. PubMed ID: 23630300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1β and TNF-α.
    Matsumoto S; Takita M; Chaussabel D; Noguchi H; Shimoda M; Sugimoto K; Itoh T; Chujo D; SoRelle J; Onaca N; Naziruddin B; Levy MF
    Cell Transplant; 2011; 20(10):1641-7. PubMed ID: 21396171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy.
    Maffi P; Bertuzzi F; De Taddeo F; Magistretti P; Nano R; Fiorina P; Caumo A; Pozzi P; Socci C; Venturini M; del Maschio A; Secchi A
    Diabetes Care; 2007 May; 30(5):1150-5. PubMed ID: 17259471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.
    Froud T; Baidal DA; Faradji R; Cure P; Mineo D; Selvaggi G; Kenyon NS; Ricordi C; Alejandro R
    Transplantation; 2008 Dec; 86(12):1695-701. PubMed ID: 19104407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
    Posselt AM; Szot GL; Frassetto LA; Masharani U; Tavakol M; Amin R; McElroy J; Ramos MD; Kerlan RK; Fong L; Vincenti F; Bluestone JA; Stock PG
    Transplantation; 2010 Dec; 90(12):1595-601. PubMed ID: 20978464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.
    Bertuzzi F; Marazzi M; De Carlis LG; Rampoldi AG; Bonomo M; Antonioli B; Tosca MC; Galuzzi M; De Gasperi A; Colussi G
    Transplantation; 2016 Nov; 100(11):e117-e118. PubMed ID: 27517727
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.
    Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM
    Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations.
    Berney T; Bucher P; Mathe Z; Andres A; Bosco D; Mage R; Toso C; Oberholzer J; Becker C; Philippe J; Bühler L; Morel P
    Transplant Proc; 2004 May; 36(4):1121-2. PubMed ID: 15194390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.
    Takita M; Matsumoto S; Shimoda M; Chujo D; Itoh T; Sorelle JA; Purcell K; Onaca N; Naziruddin B; Levy MF
    Clin Transplant; 2012; 26(5):E471-84. PubMed ID: 23061757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.